Clinical trial
A phase 2, randomized, open label study to evaluate the efficacy, safety, pharmacodynamics, pharmacokinetics of the anti-ALK-1 MAB PF-03446962 in combination with best supportive care vs. best supportive care alone in adult patients with advanced hepatoce
To determine whether overall survival (OS) of PF-03446962 plus best supportive care (BSC) is superior to OS of BSC in patients with advanced HCC following sorafenib failure.
| Category | Value |
|---|---|
| Study start date | 2014-04-11 |